It is  Orthros Medical’s ambition to introduce into the market Disease Modifying Osteoarthritic Drugs based on single chain, heavy chain only antibodies (VHH). Orthros Medical has a portfolio of VHH that target various aspects of inflammation as well as enzymes involved in cartilage catabolism.

Orthros Medical is developping a portfolio of therapeutics focussed on osteoarthritis. 

This by combining it’s expertise in VHH and intra articulair injection therapies formulated in controled release systems. 

The therapeutic candidates aim for a local effect over a longer period of time, increasing precision and reducing side effects, to benefit patients. 

The first candidate will be evaluated in a caninine patient model in 2022 and ready for human phase I trials soon thereafter.